SITC Press Releases

SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy

By SITC Communications posted 8 days ago
MILWAUKEE – A new manuscript series – The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer – outlines the current state of the immunotherapy field, elevates the most pressing challenges and proposes the promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. The first manuscript of the series, “ Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision ,” is available now in the Journal for ImmunoTherapy of Cancer ( JITC ). This ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma

By SITC Communications posted 14 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer

By SITC Communications posted 15 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma

By SITC Communications posted 25 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer

By SITC Communications posted 05-17-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma

By SITC Communications posted 05-17-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Announces Keynote Speakers Dr. Rafi Ahmed and Dr. Elizabeth M. Jaffee at its 39th Annual Meeting

By Thomas Martin posted 05-16-2024
SITC Announces Keynote Speakers Dr. Rafi Ahmed and Dr. Elizabeth M. Jaffee at its 39 th Annual Meeting MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) is excited to announce Rafi Ahmed, PhD, FAIO from the Emory University School of Medicine as the Keynote Speaker at its 39 th Annual Meeting and Pre-Conference Programs (SITC 2024) . SITC is also hosting Elizabeth M. Jaffee, MD, FAIO, FAACR, FACP, FAAAS from the Sidney Kimmel Cancer Center at Johns Hopkins , the 2024 recipient of the Richard V. Smalley Memorial Award and Lectureship, the society’s most prestigious award ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-unresponsive Non-muscle Invasive Bladder Cancer

By SITC Communications posted 04-24-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Publishes Recommendations on Optimal Intratumoral Immunotherapy Clinical Trial (IICT) Design

By SITC Communications posted 04-23-2024
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript “ Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer . While intratumoral immunotherapies have the potential to boost anti-tumor immune responses to overcome immunosuppressive tumor microenvironments, phase III trials evaluating them in late-stage disease have had limited success to date, in part due to the complex nature of these ...
0 comments

SITC and the NCI Announce Fourth Year of Collaboration with the New AI in IO: Computational Immuno-oncology Webinar Series

By Thomas Martin posted 04-12-2024
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated to improving patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce their collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, on the fourth Computational Immuno-oncology Webinar Series. This year’s series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO). As such, the series has been rebranded to “AI in IO: SITC-NCI Computational ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma

By SITC Communications posted 03-08-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma

By Thomas Martin posted 02-17-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer

By SITC Communications posted 01-15-2024
On January 12, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer. Full prescribing information for Keytruda will be posted here . Efficacy was evaluated in KEYNOTE-A18 (NCT04221945), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 1060 patients with cervical cancer who had not previously received definitive surgery, radiation, or systemic therapy. The trial included 596 patients with FIGO 2014 Stage III-IVA disease and 462 patients with FIGO 2014 ...
0 comments

FDA approves pembrolizumab with chemotherapy for biliary tract cancer

By SITC Communications posted 11-03-2023
On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). View full prescribing information for Keytruda . Efficacy was evaluated in KEYNOTE-966 (NCT04003636), a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1069 patients with locally advanced unresectable or metastatic BTC who had not received prior systemic therapy for advanced disease. Patients were randomized (1:1) to receive either pembrolizumab on Day ...
0 comments

FDA approves toripalimab-tpzi for nasopharyngeal carcinoma

By SITC Communications posted 10-31-2023
On October 27, 2023, the Food and Drug Administration approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC). FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. View full prescribing information for LOQTORZI . Efficacy of toripalimab-tpzi with cisplatin and gemcitabine was evaluated in JUPITER-02 (NCT03581786), ...
0 comments